Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
EMA recommends extending the indication of Zynyz (retifanlimab) for treating advanced squamous cell carcinoma of the anal canal in adults. This marks a significant step in immunotherapy options for this patient population.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.